Clinical trials: Central Obesity
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Overweight, Obesity
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
- Trial name
- NCT00402077
- Testing
- pramlintide acetate, sibutramine, phentermine
- Where
- 16 sites in United States
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Obesity
Multi-Center Pre-Bariatric Weight Loss Study
The purpose of the study is to evaluate the safety and efficacy of the GI Sleeve in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00469391
- Testing
- GI Sleeve Implantable weight loss device (EndoBarrier)
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Morphic Medical Inc.
Weight
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
LIPO-102 is under evaluation for treatment of abdominal adiposity
- Trial name
- NCT01180465
- Testing
- LIPO-102, LIPO-102 Low
- Where
- 2 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Neothetics, Inc
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in…
- Trial name
- NCT00042601
- Testing
- Pramlintide acetate
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Healthy Participants, Obesity
A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors
The main purposes of this study are: to investigate the safety and tolerability of ACI-19764 when it is administered to healthy participants and participants with cardiovascular risk factors to determine how quickly and to what…
- Conditions
- Healthy Participants, Obesity, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07463196
- Testing
- ACI-19764 at dose A1, ACI-19764 at dose A2, ACI-19764 at dose A3
- Where
- Netherlands
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- NCT02398188
- Testing
- LIPO-202
- Where
- 35 sites in United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Obesity
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.
- Trial name
- NCT07716241
- Testing
- HS-20136-2
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Obesity
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications…
- Trial name
- NCT00339014
- Testing
- Zonisamide CR and Bupropion SR
- Where
- 15 sites in United States
- Volunteers
- 611 people
- Sponsor
- Orexigen Therapeutics, Inc
Adiposity
Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
The study is designed as a prospective, mono-centric, randomized, patient blinded comparison of unidirectional barbed suture (Symmcora® mid term, UBS) vs. a conventional suture (Novosyn®, CS).
- Trial name
- BARGASTRO (NCT05433688)
- Testing
- Robotic assisted gastric bypass surgery
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Aesculap AG
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Obesity, Diabetes Mellitus Type 2
Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug
The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in obese type 2 diabetic patients on monotherapy…
- Trial name
- SYMPHONY (NCT00478595)
- Testing
- Rimonabant, Anti-diabetic monotherapy
- Where
- Japan
- Volunteers
- 458 people
- Sponsor
- Sanofi
22q11 Deletion Syndrome, DiGeorge Syndrome
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and…
- Conditions
- 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18
- Trial name
- SMART (NCT02381457)
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 20,960 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Overweight and Obesity
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
- Trial name
- EMBRAZE (NCT06445075)
- Testing
- Apitegromab, Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Scholar Rock, Inc.
Obesity
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
The REDUCE Pivotal Trial is a pivotal clinical study designed to develop valid scientific evidence regarding the safety and effectiveness of the ReShape Duo® as an adjunct to diet and exercise in the treatment of obese subjects…
- Trial name
- NCT01673698
- Testing
- ReShape Duo balloon, Diet counseling, Exercise counseling
- Where
- 8 sites in United States
- Volunteers
- 326 people
- Sponsor
- ReShape Lifesciences
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female…
- Trial name
- NCT00747929
- Testing
- S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
- Where
- 38 sites in United States
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity, Weight Loss
Obese Patients With or Without Comorbidities (RIO-North America)
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
- Trial name
- NCT00029861
- Testing
- Rimonabant (SR141716)
- Where
- 51 sites in United States, Canada
- Volunteers
- 3,045 people
- Sponsor
- Sanofi
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.
- Trial name
- NCT01508949
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S